Press release
AL Amyloidosis Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers
AL Amyloidosis Market Size
The market for AL amyloidosis has witnessed accelerated expansion in recent years, with projections indicating a surge from $3.11 billion in 2024 to $3.52 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.2%. The historical growth trajectory can be traced back to the increased awareness of AL amyloidosis amongst healthcare professionals, a rise in AL amyloidosis cases, an expanding elderly population, the growth of diagnostic centres, and advancements in cardiac imaging.
The market size of AL amyloidosis is predicted to witness a swift expansion in the upcoming years, soaring to $5.74 billion by 2029 with a compound annual growth rate (CAGR) of 13.0%. The anticipated growth during the forecast period can be linked with the escalating occurrences of blood cell DNA mutations, expanding healthcare framework, rising incidence of multiple myeloma, emergence of combined treatments, and the increased use of intensive chemotherapy. The future trends include advancements in diagnostic procedures, technological enhancements in medication delivery, developments in blood tests, creation of targeted therapies, and the implementation of artificial intelligence (AI) in diagnostic procedures.
What Key Elements Are Boosting Growth in the AL Amyloidosis Market?
The growth of the AL amyloidosis market is expected to be driven by an increasing prevalence of plasma cell disorders. Such disorders, which involve abnormal plasma cells producing excessive or abnormal antibodies, can cause potential organ damage. Several factors such as the aging population, enhanced life expectancy, and progress in diagnostic technologies have been identified as causes for this rise in plasma cell disorders. AL amyloidosis, a condition stemming from plasma cell disorders, involves the overproduction of abnormal light chain proteins, leading to amyloid deposit accumulation in the organs and tissues, thus further intensifying plasma cell dyscrasias effects. For instance, The American Cancer Society (ACS), a US-based nonprofit organization, published reports in August 2024 predicting around 35,780 new cases of multiple myeloma (19,520 in men and 16,260 in women) in 2024. Additionally, it projects around 12,540 deaths (7,020 in men and 5,520 in women). Therefore, the AL amyloidosis market's growth is fueled by the increasing prevalence of plasma cell disorders.
Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20710&type=smp
Who Are the Major Industry Players Fueling AL Amyloidosis Market Expansion?
Major companies operating in the AL amyloidosis market are Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Astellas Pharma Inc., Genmab A/S, Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Prothena Corporation plc, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Ionis Pharmaceuticals Inc., Ultromics Ltd, Neurimmune AG, Immix Biopharma Inc., Oncopeptides AB, Attralus Inc.
Which Key Developments Are Influencing the AL Amyloidosis Market?
Key players in the AL amyloidosis market are concentrating their efforts on the creation of new and effective treatments such as next-generation B-cell maturation antigen (BCMA)-directed CAR T-cell therapies. This advanced immunotherapy type involves modifying a patient's T cells to target and attack BCMA found on the surface of cancer cells, specifically in cases of multiple myeloma. For example, in September 2023, Immix Biopharma Inc., an American biopharmaceutical company, obtained U.S. Food and Drug Administration (FDA) approval for their drug NXC-201 to treat Amyloid Light Chain (AL) Amyloidosis, a serious blood disease. NXC-201, a next-generation CAR-T cell therapy, currently under clinical trials, has exhibited impressive effects on AL amyloidosis patients with a 100% hematologic response rate, showing significant improvements on organs for patients unresponsive to prior treatments.
How Is the Segmentation of the AL Amyloidosis Market Defined?
The AL amyloidosis market covered in this report is segmented -
1) By Treatment: Chemotherapy, Supportive Care, Surgery, Stem Cell Transplant, Targeted Therapy
2) By Drugs: Transthyretin Transport Inhibitor, Immunomodulatory Drugs, Monoclonal Antibodies, Proteasome Inhibitors, Other Drugs
3) By Route Of Administration: Intravenous, Oral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Chemotherapy: Conventional Chemotherapy Agents, High-Dose Chemotherapy
2) By Supportive Care: Pain Management, Organ-specific Supportive Care (Cardiac, Renal)
3) By Surgery: Organ Transplantation, Debulking Surgery
4) By Stem Cell Transplant: Autologous Stem Cell Transplant, Allogeneic Stem Cell Transplant
5) By Targeted Therapy: Monoclonal Antibodies, Proteasome Inhibitors, Kinase Inhibitors
Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/al-amyloidosis-global-market-report
What Is the Leading Region in the AL Amyloidosis Market?
North America was the largest region in the AL amyloidosis market in 2024. The regions covered in the AL amyloidosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Is Covered In The AL Amyloidosis Global Market Report?
- Market Size Analysis: Analyze the al amyloidosis Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the al amyloidosis Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the market.
- Market Contribution: Evaluate contributions of different segments to the overall al amyloidosis market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the al amyloidosis market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.
Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20710
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release AL Amyloidosis Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers here
News-ID: 3875508 • Views: …
More Releases from The Business Research Company
Global Semantic Knowledge Graphing Market Projected to Grow at 12.5% CAGR, Reach …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Semantic Knowledge Graphing Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent times, there has been significant growth in the market size of semantic knowledge graphing. It is anticipated that the market will expand from $1.49 billion in 2024 to $1.7 billion in 2025,…
Global Security Analytics Industry Outlook 2025-2029: Market Set to Cross $35.7 …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Security Analytics Market Through 2025?
The market size for security analytics has rapidly expanded in the recent past. From $17 billion in 2024, it is projected to swell up to $19.74 billion in 2025, representing a compound annual growth rate (CAGR) of…
Remote Work Revolution Fueling The Surge In Robotic Process Automation (RPA) Tec …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Robotic Process Automation (RPA) In Information Technology Industry Market Size Be by 2025?
The market size of Robotic Process Automation (RPA) in Information Technology has seen an explosive growth recently. The market is projected to expand from $1.42 billion in 2024 to $1.78 billion in 2025,…
Soaring Demand Set to Propel Remote Firmware Market to $13.58 Billion by 2029
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Remote Firmware Market Size By 2025?
The market size of remote firmware has experienced substantial growth in the past few years. It is projected to increase from $7.35 billion in 2024 to $8.37 billion in 2025, with a compound annual growth rate (CAGR) of 13.8%.…
More Releases for Amyloid
Islet Amyloid Polypeptide Market Analysis Current Landscape and Future Outlook
The global Islet Amyloid Polypeptide market is projected to reach approximately USD 255.8 million by 2033, growing at a compound annual growth rate (CAGR) of 10.1% from 2024 to 2033.
Islet Amyloid Polypeptide Market Overview
The Islet Amyloid Polypeptide market is gaining traction due to its critical role in metabolic disorders, particularly in type 2 diabetes research and treatment. Islet Amyloid Polypeptide (IAPP), also known as amylin, is closely associated with insulin…
Cerebral Amyloid Angiopathy Pipeline Landscape: 10+ Emerging Therapies Targeting …
Cerebral Amyloid Angiopathy (CAA) is a progressive cerebral small vessel disease marked by amyloid-β (Aβ) protein deposition in the walls of leptomeningeal and cortical blood vessels. Often occurring in the elderly and closely linked with Alzheimer's disease, CAA contributes significantly to cognitive impairment, spontaneous intracerebral hemorrhage, and cerebral microbleeds. Despite its high clinical burden, there are currently no approved disease-modifying therapies specifically for CAA, and diagnosis remains challenging without advanced…
Amyloid Peptides Market to Witness Astonishing Growth by 2029
Amyloid Peptides Market is anticipated to grow at a significant CAGR during the forecast period. Growing favourable investment, as well as reimbursement facilities in the developed economic countries, is one of the major factors that is expected to fuel the global amyloid peptides market during the forecast period. Moreover, a growing number of clinical trials and research activities to develop treatment and drugs for Alzheimer's are also anticipated to boost…
Amyloid Peptides Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Amyloid Peptides Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Amyloid Peptides players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Amyloid Peptides with respect to individual growth…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
Islet Amyloid Polypeptide: Therapeutic Developments to Witness Growth
Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Islet amyloid polypeptide (IAPP) or Amylin is a peptide hormone. This hormone is released from pancreatic beta cells following food intake to regulate blood glucose levels and act as a satiation signal. It inhibits insulin-stimulated glucose utilization and glycogen deposition in muscle. The molecules developed by companies in Phase II, Phase I and Preclinical stages…
